title: Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma.
abstract: Loss of heterozygosity (LOH) represents the most frequent genetic alteration observed in hepatocellular carcinoma (HCC). Chromosome 16q is of particular interest as it exhibits LOH in 29% of HCC tumors and is frequently lost in breast, prostate, ovarian and gastric carcinomas. We genotyped 157 HCC tumors for 17 microsatellite markers distributed on chromosome 16q and determined a common region of LOH localized between the markers D16S518 and D16S504. By refining the boundaries of two interstitial LOH and two homozygous deletions, the critical region was delimited to 180 kb between D16S3096 and D16S3029. This region is located in intron 8 of the WWOX/FOR gene, but a search for mutations in all coding exons of this gene in 27 HCC tumors and cell lines did not reveal any tumor somatic alterations. Furthermore, by RT-PCR, no abnormal transcripts of this WWOX/FOR gene was detected in nine HCC cell lines. Finally, analysis of the p53 gene mutations with the clinical parameters of all tumors revealed that the two homozygous deletions have occurred in tumors presenting a R249S mutation. Our data revealed a relationship between chromosome 16q homozygous deletions and R249S p53 mutations in tumors where the patient had been exposed to aflatoxin B1 (P=0.002). These results are consistent with a role of aflatoxin B1 in the instability of chromosome 16q at the fragile site FRA16D. However, the nature of the specific gene that is altered during hepatocarcinogenesis remains to be elucidated.
authors.affiliation: INSERM U434, CEPH 27 Rue Juliette Dodu 75010 Paris, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Yakicier
authors.forename: P
authors.initials: P
authors.lastname: Legoix
authors.forename: C
authors.initials: C
authors.lastname: Vaury
authors.forename: L
authors.initials: L
authors.lastname: Gressin
authors.forename: E
authors.initials: E
authors.lastname: Tubacher
authors.forename: F
authors.initials: F
authors.lastname: Capron
authors.forename: J
authors.initials: J
authors.lastname: Bayer
authors.forename: C
authors.initials: C
authors.lastname: Degott
authors.forename: C
authors.initials: C
authors.lastname: Balabaud
authors.forename: J
authors.initials: J
authors.lastname: Zucman-Rossi
mesh_terms: D016604:Aflatoxin B1; D000483:Alleles; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000235:genetics*; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D002885:Chromosomes, Human, Pair 16; D005091:Exons; D005434:Flow Cytometry; D016158:Genes, p53 / Q000235:genetics; D005838:Genotype; D006720:Homozygote; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000235:genetics*; D019656:Loss of Heterozygosity; D018895:Microsatellite Repeats; D008957:Models, Genetic; D009154:Mutation; D012333:RNA, Messenger / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D002273:Carcinogens; D012333:RNA, Messenger; D016604:Aflatoxin B1